MME and heart failure: The neprilysin is also anticipated to be a promising biotarget for the reduction of CV risk in patients with chronic kidney disease (CKD) and cross-sectional study showed the usefulness of neprilysin for heart failure diagnosis in dialysis patients (14–18).